SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. Some of the statements made herein constitute forward-looking statements. These statements relate to future performance or anticipated plans and are identified by words such as “may,” “will,” “should,” “expect,” “could,” “scheduled,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “potential,” “propose” and “continue” or negative variants of such terms. These statements are only estimates of future performance. Actual performance or events may not meet such expectations or estimates and may, in fact, differ materially. Although we believe that the expectations reflected in the forward-looking statements made herein are reasonable, we cannot and do not guarantee future results, levels of activity, performance or achievements. Moreover, we do not assume any responsibility for the accuracy and completeness of such forward-looking statements in the future. We do not plan and, subject to applicable law, undertake no obligation to update any of the forward-looking statements made herein in order to conform such statements to our actual results. Any graphics or charts that depict forward-looking statements herein are subject to the same limitations.
BackBeat CNT, PHC stimulation and the ModeratoTM System have not been approved for an Investigational Device Evaluation (IDE) clinical study in the US. It is exclusively for clinical investigations for the treatment of hypertension outside the US. Not available for commercial sale.
Virtue® SEB has not yet been approved for an Investigational Device Evaluation (IDE). Not available for commercial sale.
© 2019 Orchestra BioMed. Virtue®, FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.